Bojan Lalovic

1.7k total citations
23 papers, 992 citations indexed

About

Bojan Lalovic is a scholar working on Experimental and Cognitive Psychology, Cognitive Neuroscience and Immunology. According to data from OpenAlex, Bojan Lalovic has authored 23 papers receiving a total of 992 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Experimental and Cognitive Psychology, 5 papers in Cognitive Neuroscience and 5 papers in Immunology. Recurrent topics in Bojan Lalovic's work include Sleep and related disorders (5 papers), Sleep and Wakefulness Research (5 papers) and Pain Management and Opioid Use (4 papers). Bojan Lalovic is often cited by papers focused on Sleep and related disorders (5 papers), Sleep and Wakefulness Research (5 papers) and Pain Management and Opioid Use (4 papers). Bojan Lalovic collaborates with scholars based in United States, United Kingdom and Japan. Bojan Lalovic's co-authors include Danny D. Shen, Evan D. Kharasch, Brian Phillips, William N. Howald, Sudha Visvanathan, Steven J. Padula, James G. Krueger, Alan Menter, Frank Wagner and Alan M. Solinger and has published in prestigious journals such as Blood, Journal of Allergy and Clinical Immunology and Clinical Pharmacology & Therapeutics.

In The Last Decade

Bojan Lalovic

23 papers receiving 966 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bojan Lalovic United States 11 329 239 236 235 205 23 992
Miriam Saiz‐Rodríguez Spain 19 47 0.1× 176 0.7× 77 0.3× 140 0.6× 351 1.7× 58 984
Daniel T. Barratt Australia 16 273 0.8× 296 1.2× 165 0.7× 27 0.1× 212 1.0× 34 952
J.F. Horga Spain 17 63 0.2× 88 0.4× 122 0.5× 34 0.1× 108 0.5× 47 729
Pär Hallberg Sweden 18 24 0.1× 104 0.4× 81 0.3× 74 0.3× 192 0.9× 62 1.1k
Eliane Fuseau France 17 50 0.2× 249 1.0× 213 0.9× 29 0.1× 64 0.3× 40 1.0k
Ram P. Kapil United States 14 98 0.3× 60 0.3× 145 0.6× 16 0.1× 70 0.3× 46 731
Alberto Chiappe Switzerland 7 128 0.4× 179 0.7× 81 0.3× 82 0.3× 454 2.2× 8 960
Carmen Belmonte Spain 14 29 0.1× 111 0.5× 36 0.2× 44 0.2× 188 0.9× 21 455
Rashmi Patwardhan United States 20 62 0.2× 330 1.4× 88 0.4× 22 0.1× 412 2.0× 35 1.2k
Pablo Zubiaur Spain 17 47 0.1× 164 0.7× 48 0.2× 30 0.1× 332 1.6× 73 877

Countries citing papers authored by Bojan Lalovic

Since Specialization
Citations

This map shows the geographic impact of Bojan Lalovic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bojan Lalovic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bojan Lalovic more than expected).

Fields of papers citing papers by Bojan Lalovic

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bojan Lalovic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bojan Lalovic. The network helps show where Bojan Lalovic may publish in the future.

Co-authorship network of co-authors of Bojan Lalovic

This figure shows the co-authorship network connecting the top 25 collaborators of Bojan Lalovic. A scholar is included among the top collaborators of Bojan Lalovic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bojan Lalovic. Bojan Lalovic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Majid, Oneeb, Youfang Cao, Brian A. Willis, et al.. (2024). Population pharmacokinetics and exposure–response analyses of safety (ARIA‐E and isolated ARIA‐H) of lecanemab in subjects with early Alzheimer's disease. CPT Pharmacometrics & Systems Pharmacology. 13(12). 2111–2123. 6 indexed citations
2.
3.
Goteti, Kosalaram, Mindy Magee, Sven Mensing, et al.. (2023). Opportunities and Challenges of Disease Progression Modeling in Drug Development – An IQ Perspective. Clinical Pharmacology & Therapeutics. 114(2). 266–274. 5 indexed citations
4.
Rawal, Sumit, Takuya Yagi, Kristin R. Wildsmith, et al.. (2023). E2814: an anti‐tau therapy engages its CNS target and affects the downstream tangle‐specific biomarker MTBR‐tau243 in Dominantly Inherited Alzheimer’s Disease. Alzheimer s & Dementia. 19(S24). e082771–e082771. 6 indexed citations
5.
Lalovic, Bojan, Ishani Landry, Margaret Moline, Larisa Reyderman, & Ziad Hussein. (2022). Exposure–Response Analyses of Polysomnography and Subjective Sleep Efficacy End Points From the Phase 3 Trials of Lemborexant, a Dual Orexin Receptor Antagonist for the Treatment of Insomnia. The Journal of Clinical Pharmacology. 63(4). 498–511. 3 indexed citations
6.
7.
McAdams, Ryan M., Daniel Pak, Bojan Lalovic, Brian Phillips, & Danny D. Shen. (2020). Dexmedetomidine Pharmacokinetics in Neonates with Hypoxic-Ischemic Encephalopathy Receiving Hypothermia. Anesthesiology Research and Practice. 2020. 1–15. 30 indexed citations
8.
Lalovic, Bojan, Oneeb Majid, Jagadeesh Aluri, et al.. (2020). Population Pharmacokinetics and Exposure‐Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder. The Journal of Clinical Pharmacology. 60(12). 1642–1654. 16 indexed citations
9.
Landry, Ishani, Kenya Nakai, Jim Ferry, et al.. (2020). Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single‐Dose and Multiple‐Ascending‐Dose Phase 1 Studies in Healthy Adults. Clinical Pharmacology in Drug Development. 10(2). 153–165. 45 indexed citations
10.
Visvanathan, Sudha, Patrick Baum, Richard Vinisko, et al.. (2018). Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab. Journal of Allergy and Clinical Immunology. 143(6). 2158–2169. 58 indexed citations
11.
Krueger, James G., Laura K. Ferris, Alan Menter, et al.. (2015). Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. Journal of Allergy and Clinical Immunology. 136(1). 116–124.e7. 194 indexed citations
12.
13.
Lalovic, Bojan, et al.. (2010). Modeling Dropout From Adverse Event Data: Impact of Dosing Regimens Across Pregabalin Trials in the Treatment of Generalized Anxiety Disorder. The Journal of Clinical Pharmacology. 51(5). 706–718. 4 indexed citations
14.
Miller, Raymond, Kaori Ito, & Bojan Lalovic. (2010). Models for Event‐Driven Data: Longitudinal Daily Adverse Event and Dropout. The Journal of Clinical Pharmacology. 50(S9). 58S–62S. 1 indexed citations
15.
Zhong, Wei-Zhu, Bojan Lalovic, & Jenny Zhan. (2009). Characterization of in vitro and in vivo metabolism of AG-024322, a novel cyclin-dependent kinase (CDK). Health. 1(4). 249–262. 10 indexed citations
16.
Lalovic, Bojan, et al.. (2006). Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: Role of circulating active metabolites. Clinical Pharmacology & Therapeutics. 79(5). 461–479. 332 indexed citations
17.
Kharasch, Evan D., Dale Whittington, Christine Hoffer, et al.. (2005). Paradoxical Role of Cytochrome P450 3A in the Bioactivation and Clinical Effects of Levo-??-Acetylmethadol. Clinical Pharmacokinetics. 44(7). 731–751. 9 indexed citations
18.
Burbacher, Thomas M., Danny D. Shen, Bojan Lalovic, et al.. (2004). Chronic maternal methanol inhalation in nonhuman primates (Macaca fascicularis): Exposure and toxicokinetics prior to and during pregnancy. Neurotoxicology and Teratology. 26(2). 201–221. 4 indexed citations
19.
Lalovic, Bojan, et al.. (2004). QUANTITATIVE CONTRIBUTION OF CYP2D6 AND CYP3A TO OXYCODONE METABOLISM IN HUMAN LIVER AND INTESTINAL MICROSOMES. Drug Metabolism and Disposition. 32(4). 447–454. 207 indexed citations
20.
Storek, Jan, et al.. (2002). Kinetics of B, CD4 T, and CD8 T Cells Infused into Humans: Estimates of Intravascular:Extravascular Ratios and Total Body Counts. Clinical Immunology. 102(3). 249–257. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Miriam Saiz‐Rodríguez Breakdown of academic impact, for papers by Daniel T. Barratt Breakdown of academic impact, for papers by J.F. Horga Breakdown of academic impact, for papers by Pär Hallberg Breakdown of academic impact, for papers by Eliane Fuseau Breakdown of academic impact, for papers by Ram P. Kapil Breakdown of academic impact, for papers by Alberto Chiappe Breakdown of academic impact, for papers by Carmen Belmonte Breakdown of academic impact, for papers by Rashmi Patwardhan Breakdown of academic impact, for papers by Pablo Zubiaur
Rankless by CCL
2026